- Rheumatologie-App Injektionstechnik
- Neue Studien
- Kongress Highlights
- EULAR 2018
- EULAR 2017
- EULAR 2016
- EULAR 2015
- EULAR 2014
- ACR 2018
- ACR 2017
- ACR 2015
- ACR 2014
- Rheuma Top 2018
- Rheuma Top 2017
- Rheuma Top 2015
- Rheuma Top 2014
- SlideSet RA
- FOCUS «Der Fuss»
- FOCUS «Kinderrheumatologie»
EULAR 2017 | Daily Highlights
RISK FACTORS FOR SEVERE INFECTION AND RATIONALE FOR IMMUNOGLOBULIN MONITORING DURING RITUXIMAB TREATMENT IN AUTOIMMUNE RHEUMATIC DISEASESAbstract: SAT0556
Authors: M. Y. Md Yusof1,2,*, E. M. Vital1,2, D. McElvenny3, E. M. Hensor1,2, S. Das2, M. H. Buch1,2, P. Emery1,2, S. Savic1,2
1NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, 2Rheumatology, LEEDS INSTITUTE OF RHEUMATIC AND MUSCULOSKELETAL MEDICINE, UNIVERSITY OF LEEDS, Leeds, 3Institute of Population Health, University of Manchester, Manchester, United Kingdom
Rituximab (RTX) has been used in the treatment of various autoimmune rheumatic diseases (AIRDs) for over a decade. Repeat cycles are effective for maintenance but may lead to hypogammaglobulinaemia. Low IgG at baseline has been associated with post-treatment infection rate but may be confounded by other clinical variables and fully adjusted models with method for handling missing data have not been presented. Importance of post-treatment change in Igs has also not been proven.
To evaluate risk factors for severe infection in multivariable analysis and assess outcome of hypogammaglobulinaemia.
The first 700 consecutive patients with AIRDs treated with RTX at a single centre were studied. Each cycle of RTX consisted of 2x1000mg infusions repeated on clinical relapse. IgM, IgA and IgG levels were measured at baseline and 4-6 months after each cycle. Multiple imputation was used for missing data. Baseline factors for predicting serious infection and low Ig were tested using univariable and multivariable (MVA) logistic regression analyses.
550 patients were female, median age(IQR) at RTX initiation 58(46-68) years and median disease duration(IQR) 7.9(3.4-15.0) years. 506(72%) had RA, 94(13%) SLE, 49(7%) AAV, 14(2%) DM, 5(1%) APS, 6(1%) SSc and 26(4%) other CTD. 364(52%) were biologic-naïve and 515(74%) were on concomitant DMARDs. Total follow-up: 2940 patient-years (PY). 284 serious infections were recorded in 179 patients (9.7/100 PY); 88 cases within 12 months of cycle 1 (C1). In MVA, previous severe infection (OR 10.7, 95% CI 5.8-19.5), low IgG (OR 3.6, 95% CI 1.5-8.6), previous cancer (OR 2.9, 95% CI 1.2-6.6) and chronic lung disease (OR 1.7, 95% CI 0.9-3.1) increased the odds of a severe infection within 12 months of C1. A diagnosis of CTD was associated with lower risk (OR 0.5, 95% CI 0.2-0.9). Low IgG at RTX initiation was predicted by older age, previous cancer, RA diagnosis, previous severe infection and previous treatment with cyclophosphamide. In C1-C3, higher rate of change in IgA and IgG levels were associated with serious infections (Figure 1). Overall, only 7(1%) of the patients required Ig replacement in this cohort.
Factors associated with serious infection at RTX initiation include previous serious infection, low IgG, previous cancer, a diagnosis of RA and chronic lung disease. This is the first study to show the rationale for monitoring the rate of change in Ig levels during repeat cycles of RTX, with reduction in all Ig subclasses being associated with increased risk of post-treatment infection. Further analysis including predictors of serious infections in repeat cycles is in progress and will be used to develop guidelines for safety monitoring of rituximab.
This research was funded/supported by the National Institute for Health Research (NIHR) and NIHR Leeds Musculoskeletal Biomedical Research Unit based at Leeds Teaching Hospitals NHS Trust; (DRF-2014-07-155). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Disclosure of Interest:
In this epidemiologic single center study 700 patients with autoummune rheumatic diseases treated with rituximab (RTX) were analyzed with regard to risk factors for infections. In a total of 2940 patient-years 284 infections were noted in 197 patients; 88 cases within the first 12 month after the first treatment cycle.The risk factors associated with serious infection at RTX initiation include previous severe infections, low IgG, previous cancer, a diagnosis of RA and chronic lung disease and previous treatment with cyclophsophamid. Patients with connective tissue diesease have less infections than patients with vasculitides or rheumatoid arthritis. For the prevention of serious infections we should be aware of these risk factors and measure the total IgG level before each RTX cycle. The cut-off level is > 5 g/l.
Dr. Thomas Langenegger